Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐TNF therapy

The discontinuation of anti‐tumour necrosis factor (anti‐TNF) treatment in inflammatory bowel disease (IBD) patients in remission could be considered.

[1]  P. Rutgeerts,et al.  Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  E. Louis,et al.  Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease , 2015, Clinical Pharmacokinetics.

[3]  J. Gisbert,et al.  Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease. , 2015, Current drug metabolism.

[4]  J. Gisbert,et al.  Effectiveness of Adalimumab in Perianal Fistulas in Crohn’s Disease Patients Naive to Anti-TNF Therapy , 2015, Journal of clinical gastroenterology.

[5]  J. Gisbert,et al.  How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? , 2014, Expert opinion on drug safety.

[6]  Wei-xin Liu,et al.  Mucosal Healing Did Not Predict Sustained Clinical Remission in Patients with IBD after Discontinuation of One-Year Infliximab Therapy , 2014, PloS one.

[7]  S. Cross,et al.  Outcome of elective withdrawal of anti-tumour necrosis factor-&agr; therapy in patients with Crohn's disease in established remission* , 2014, Journal of Crohn's & colitis.

[8]  P. Rutgeerts,et al.  Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  M. Regueiro,et al.  Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  B. Pariente,et al.  Review article: why, when and how to de‐escalate therapy in inflammatory bowel diseases , 2014, Alimentary pharmacology & therapeutics.

[11]  K. Whelan,et al.  Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. , 2014, Journal of Crohn's & colitis.

[12]  A. Amiot,et al.  Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[13]  A. Ristimäki,et al.  Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? , 2014, Journal of Crohn's & colitis.

[14]  E. Louis,et al.  Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohn's Disease , 2014, Inflammatory bowel diseases.

[15]  M. Färkkilä,et al.  Outcome After Discontinuation of TNF&agr;-blocking Therapy in Patients with Inflammatory Bowel Disease in Deep Remission , 2014, Inflammatory bowel diseases.

[16]  A. Keshavarzian,et al.  The relationship between coping, health competence and patient participation among patients with inactive inflammatory bowel disease. , 2014, Journal of Crohn's & colitis.

[17]  C. J. Woude,et al.  340 Anti-TNF is Safe to Stop in the Second Trimester of Pregnancy in IBD Women in Remission , 2014 .

[18]  R. Ni,et al.  Chronic pouchitis is associated with pouch polyp formation in patients with underlying ulcerative colitis. , 2014, Journal of Crohn's & colitis.

[19]  L. Guidi,et al.  342 Retreatment With Infliximab in Inflammatory Bowel Disease: Tolerability and Effectiveness of Different Re-Induction Regimens , 2014 .

[20]  J. Bassaganya-Riera,et al.  Stopping Anti-TNF Agents in Patients with Crohn's Disease in Remission: Is It a Feasible Long-term Strategy? , 2014, Inflammatory bowel diseases.

[21]  K. Farkas,et al.  Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy. , 2014, World journal of gastroenterology.

[22]  M. Marino,et al.  P401 Outcome of infliximab discontinuation in IBD patients and therapy rechallenging in relapsers: Single centre preliminary data , 2014 .

[23]  P. Balestrieri,et al.  P402 Normalized wall thickness at MRE predicts clinical remission in Crohn's disease after infliximab discontinuation: a 5 years follow-up , 2014 .

[24]  P. Gonzalez,et al.  P405 Mucosal healing in patients with ulcerative colitis treated with infliximab. What happens after treatment is discontinued , 2014 .

[25]  M. Palau,et al.  P398 Outcome of treatment with biological agents in Crohn's disease: 117 patients in 5 years from a tertiary referral center , 2014 .

[26]  L. Guidi,et al.  P363 Retreatment with infliximab in inflammatory bowel disease: tolerability and effectiveness of different re-induction regimens , 2014 .

[27]  E. Leo,et al.  P487 Factors influencing recurrence following suspension of biological treatment. Importance of mucosal healing , 2014 .

[28]  J. Sanderson,et al.  Reassessment of Crohn's disease treated with at least 12 months of anti-TNF therapy: how likely is treatment withdrawal? , 2013, Frontline Gastroenterology.

[29]  K. Farkas,et al.  Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy , 2013, Scandinavian journal of gastroenterology.

[30]  B. Shen.  Pouchitis: what every gastroenterologist needs to know. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  E. Louis,et al.  Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring , 2013, Gut.

[32]  M. Giakoumis,et al.  Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis. , 2013, Journal of Crohn's & colitis.

[33]  B. Burnand,et al.  When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. , 2013, Journal of Crohn's & colitis.

[34]  J. Gisbert,et al.  Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era , 2013, Alimentary pharmacology & therapeutics.

[35]  G. D'Haens,et al.  Management of Postoperative Recurrence of Crohn's Disease , 2013, Digestive Diseases.

[36]  J. Gisbert,et al.  Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease , 2013, The American Journal of Gastroenterology.

[37]  A. Ford,et al.  Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials , 2013, The American Journal of Gastroenterology.

[38]  W. Bemelman,et al.  Ten Years of Infliximab for Crohn’s Disease: Outcome in 469 Patients from 2 Tertiary Referral Centers , 2013, Inflammatory bowel diseases.

[39]  M. Kamm,et al.  Predictors for developing intestinal failure in patients with Crohn's disease , 2013, Journal of gastroenterology and hepatology.

[40]  P. Doldo,et al.  P.02.11 WITHDRAWAL OF INFLIXIMAB (IFX) AFTER ACHIEVING REMISSION: OUTCOME IN A COHORT OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS , 2013 .

[41]  E. Kuipers,et al.  Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[42]  O. Dewit,et al.  Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. , 2013, Journal of Crohn's & colitis.

[43]  E. Paulssen,et al.  Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease , 2013, Scandinavian journal of gastroenterology.

[44]  M. McAlindon,et al.  P392 Outcomes after elective withdrawal of anti-TNF therapy in Crohn's disease: a multicentre study , 2013 .

[45]  J. C. Gallego,et al.  P403 Predictors of relapse after discontinuing anti-TNF therapy in Crohn's disease patients on deep remission , 2013 .

[46]  K. Farkas,et al.  Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy , 2013, Alimentary pharmacology & therapeutics.

[47]  Ren Mao,et al.  Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta‐analysis of prospective studies , 2012, Inflammatory bowel diseases.

[48]  Clarence K. Wong,et al.  Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. , 2012, World journal of gastroenterology.

[49]  A. Harris,et al.  A prospective study of infliximab withdrawal after 12 months of treatment in patients with Crohn's disease: how will NICE guidance affect patient care? , 2012, Clinical medicine.

[50]  J. Gisbert,et al.  Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease , 2012, Alimentary pharmacology & therapeutics.

[51]  A. Griffiths,et al.  Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. , 2012, Journal of Crohn's & colitis.

[52]  J. Seidelin,et al.  Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study , 2012, Scandinavian journal of gastroenterology.

[53]  M. Vos,et al.  P274 Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohn's disease patients. A sub-analysis of the STORI study , 2012 .

[54]  F. Vasseur,et al.  Long‐term outcome of treatment with infliximab in pediatric‐onset Crohn's disease: A population‐based study , 2011, Inflammatory bowel diseases.

[55]  W. Reinisch,et al.  Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti‐TNF‐α therapy , 2011, Alimentary pharmacology & therapeutics.

[56]  S. Ben-Horin,et al.  Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[57]  J. Gisbert,et al.  Effectiveness of a Dose “De-Escalation” Strategy With Anti-TNF Drugs in Patients With Crohn's Disease (CD) , 2011 .

[58]  J. Gisbert,et al.  Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. , 2011, Current pharmaceutical biotechnology.

[59]  P. Moayyedi,et al.  Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[60]  M. Regueiro.  Management and prevention of postoperative Crohn's disease. , 2011, Gastroenterology & hepatology.

[61]  S. Schreiber,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? , 2011, The American Journal of Gastroenterology.

[62]  P. Rutgeerts,et al.  Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[63]  Clarence K. Wong,et al.  Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohort , 2010, Alimentary pharmacology & therapeutics.

[64]  S. Cucchiara,et al.  CO12 LONG TERM EFFICACY OF INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE AT A SINGLE TERTIARY CENTER , 2010 .

[65]  M. Geraci,et al.  Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[66]  A. Gasbarrini,et al.  W1288 Long-Term Scheduled Therapy With Infliximab in Inflammatory Bowel Disease: A Single-Centre Observational Study , 2010 .

[67]  T. Mimori,et al.  Extended Report , 2022 .

[68]  P. Rutgeerts,et al.  Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.

[69]  J. Belaiche,et al.  Anti-TNF and Crohn's disease: when should we stop? , 2010, Current drug targets.

[70]  E. Cabré,et al.  Infliximab Reintroduction is Not Associated to a Higher Rate of Immune-related Adverse Effects in Patients With Inflammatory Bowel Disease Initially Treated With a Three-infusion Induction Regimen , 2010, Journal of clinical gastroenterology.

[71]  P. Rutgeerts,et al.  Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.

[72]  M. Regueiro,et al.  Infliximab prevents Crohn's disease recurrence after ileal resection. , 2009, Gastroenterology.

[73]  J. Gisbert,et al.  Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.

[74]  F. Nagy,et al.  Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease? , 2008, Journal of Crohn's & colitis.

[75]  J. Lindsay,et al.  Health‐economic analysis: cost‐effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease – modelling outcomes in active luminal and fistulizing disease in adults , 2008, Alimentary pharmacology & therapeutics.

[76]  L. Guidi,et al.  Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn’s disease with anal endosonographic monitoring: a single-centre experience , 2008, Techniques in Coloproctology.

[77]  Yoshiya Tanaka,et al.  Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission , 2008, Modern rheumatology.

[78]  J. Hugot,et al.  12-Month Follow-up After Successful Infliximab Therapy in Pediatric Crohn Disease , 2008, Journal of pediatric gastroenterology and nutrition.

[79]  M. Vatn,et al.  Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[80]  M. Ribolsi,et al.  Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. , 2007, World journal of gastroenterology.

[81]  J. Gisbert,et al.  Papel de los marcadores biológicos en la enfermedad inflamatoria intestinal , 2007 .

[82]  E. Cabré,et al.  Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? , 2005, Alimentary pharmacology & therapeutics.

[83]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[84]  M. Bala,et al.  Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.

[85]  M. Peppercorn,et al.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.

[86]  G. Marchal,et al.  Magnetic Resonance Imaging of the Effects of Infliximab on Perianal Fistulizing Crohn's Disease , 2003, American Journal of Gastroenterology.

[87]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[88]  P. Rutgeerts,et al.  Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. , 1984, Gut.

[89]  U. Kopylov,et al.  Optimizing anti-TNF treatments in inflammatory bowel disease. , 2014, Autoimmunity reviews.

[90]  P. Higgins,et al.  Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). , 2014, Journal of Crohn's & colitis.

[91]  R. Porcher,et al.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. , 2012, Gastroenterology.

[92]  M. Regueiro,et al.  Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. , 2012, Inflammatory bowel diseases.

[93]  G. Porro,et al.  Biologic Therapy for Inflammatory Bowel Disease , 2012, Drugs.

[94]  L. Peyrin-Biroulet,et al.  Clinical implications of mucosal healing for the management of IBD , 2010, Nature Reviews Gastroenterology &Hepatology.

[95]  J. Gisbert,et al.  Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[96]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[97]  J. Mate,et al.  [Role of biological markers in inflammatory bowel disease]. , 2007, Gastroenterologia y hepatologia.

[98]  Alexander Fraser,et al.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.

[99]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .